Next Article in Journal
Chlorella pyrenoidosa Polysaccharide CPP-3a Promotes M1 Polarization of Macrophages via TLR4/2-MyD88-NF-κB/p38 MAPK Signaling Pathways
Next Article in Special Issue
Salt-Adapted Microorganisms: A Promising Resource for Novel Anti-Cancer Drug Discovery
Previous Article in Journal
Multifaceted Marine Peptides and Their Therapeutic Potential
Previous Article in Special Issue
Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Novel Diketopiperazine Derivative, Compound 5-3, Selectively Inhibited the Proliferation of FLT3-ITD Mutant Acute Myeloid Leukemia (AML) Cells

1
Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Rd, Qingdao 266003, China
2
Marine Biomedical Research Institute of Qiangdao, 23 Hongkong East Rd, Qingdao 266003, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Mar. Drugs 2025, 23(7), 289; https://doi.org/10.3390/md23070289
Submission received: 9 June 2025 / Revised: 8 July 2025 / Accepted: 10 July 2025 / Published: 16 July 2025

Abstract

The internal tandem duplication mutation of FMS-like tyrosine kinase 3 (FLT3-ITD) is associated with high recurrence and mortality rates in acute myeloid leukemia (AML), making it a critical target for anti-AML therapies. Plinabulin is a diketopiperazines derivative that exhibits extensive anti-cancer potency by targeting β-tubulin. We designed and synthesized a novel FLT3 inhibitor, namely 5-3, based on the structure of plinabulin and evaluated its effect on FLT3-ITD mutant AML cells. The results indicated that 5-3 potently and selectively inhibits the growth of mutant FLT3-expressingleukemia cells, and had no effect on FLT3 wide-type cancer cells, suggesting the antiproliferative activity of 5-3 depends highly on FLT3-ITD expression. Mechanically, 5-3 significantly suppressed the phosphorylation of FLT3 signaling pathway, including STAT5, Erk and Akt. Moreover, the efficiency of compound 5-3 is not associated with Plinabulin’s typical target, β-tubulin. In conclusion, the study identified diketopiperazine derivative as a novel FLT3-ITD selective inhibitor. These results demonstrated that 5-3 might be a drug candidate for the treatment of FLT3-ITD-positive AML.
Keywords: acute myeloid leukemia; FLT3-ITD mutation; diketopiperazine; tubulin acute myeloid leukemia; FLT3-ITD mutation; diketopiperazine; tubulin
Graphical Abstract

Share and Cite

MDPI and ACS Style

Bi, S.; Cao, Y.; Fang, S.; Chu, Y.; Zhang, Z.; Li, M.; Yu, R.; Yang, J.; Tang, Y.; Qiu, P. The Novel Diketopiperazine Derivative, Compound 5-3, Selectively Inhibited the Proliferation of FLT3-ITD Mutant Acute Myeloid Leukemia (AML) Cells. Mar. Drugs 2025, 23, 289. https://doi.org/10.3390/md23070289

AMA Style

Bi S, Cao Y, Fang S, Chu Y, Zhang Z, Li M, Yu R, Yang J, Tang Y, Qiu P. The Novel Diketopiperazine Derivative, Compound 5-3, Selectively Inhibited the Proliferation of FLT3-ITD Mutant Acute Myeloid Leukemia (AML) Cells. Marine Drugs. 2025; 23(7):289. https://doi.org/10.3390/md23070289

Chicago/Turabian Style

Bi, Shijie, Yating Cao, Shiyuan Fang, Yanyan Chu, Zixuan Zhang, Meng Li, Rilei Yu, Jinbo Yang, Yu Tang, and Peiju Qiu. 2025. "The Novel Diketopiperazine Derivative, Compound 5-3, Selectively Inhibited the Proliferation of FLT3-ITD Mutant Acute Myeloid Leukemia (AML) Cells" Marine Drugs 23, no. 7: 289. https://doi.org/10.3390/md23070289

APA Style

Bi, S., Cao, Y., Fang, S., Chu, Y., Zhang, Z., Li, M., Yu, R., Yang, J., Tang, Y., & Qiu, P. (2025). The Novel Diketopiperazine Derivative, Compound 5-3, Selectively Inhibited the Proliferation of FLT3-ITD Mutant Acute Myeloid Leukemia (AML) Cells. Marine Drugs, 23(7), 289. https://doi.org/10.3390/md23070289

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop